These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 39330003

  • 1. Outcomes of First Subsequent Taxane Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Who Previously Received Docetaxel Intensification for Metastatic Castration-Sensitive Prostate Cancer.
    Robin G, Basappa NS, North S, Ghosh S, Kolinsky M.
    Curr Oncol; 2024 Aug 29; 31(9):5080-5087. PubMed ID: 39330003
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. No significant impact of prior treatment profile with docetaxel on the efficacy of cabazitaxel in Japanese patients with metastatic castration-resistant prostate cancer.
    Miyake H, Sugiyama T, Aki R, Matsushita Y, Tamura K, Motoyama D, Ito T, Otsuka A.
    Med Oncol; 2017 Aug 29; 34(8):141. PubMed ID: 28718092
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study.
    Flippot R, Telli T, Velev M, Fléchon A, De Vries-Brilland M, Turpin L, Bergman A, Turco F, Mahammedi H, Fendler WP, Giraudet AL, Josset Q, Montravers F, Vogel W, Gillessen S, Berardi Vilei S, Herrmann K, Kryza D, Paone G, Hadaschik B, Merlin C, Dufour PA, Bernard-Tessier A, Naoun N, Patrikidou A, Garcia C, Foulon S, Pagès A, Fizazi K.
    Eur Urol Oncol; 2024 Oct 29; 7(5):1132-1140. PubMed ID: 38664139
    [Abstract] [Full Text] [Related]

  • 6. Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial.
    Meisel A, von Felten S, Vogt DR, Liewen H, de Wit R, de Bono J, Sartor O, Stenner-Liewen F.
    Eur J Cancer; 2016 Mar 29; 56():93-100. PubMed ID: 26829012
    [Abstract] [Full Text] [Related]

  • 7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.
    JAMA Oncol; 2015 Aug 29; 1(5):582-91. PubMed ID: 26181238
    [Abstract] [Full Text] [Related]

  • 8. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.
    Eur J Cancer; 2014 Jun 29; 50(9):1602-9. PubMed ID: 24725337
    [Abstract] [Full Text] [Related]

  • 9. Patient characteristics and overall survival in patients with post-docetaxel metastatic castration-resistant prostate cancer in the community setting.
    Oh WK, Miao R, Vekeman F, Sung J, Cheng WY, Gauthier-Loiselle M, Dhawan R, Duh MS.
    Med Oncol; 2017 Aug 10; 34(9):160. PubMed ID: 28795333
    [Abstract] [Full Text] [Related]

  • 10. Real-World Treatment Patterns Among Patients With Metastatic Castration-Resistant Prostate Cancer: Results From an International Study.
    Barata PC, Leith A, Ribbands A, Montgomery R, Last M, Arondekar B, Ivanova J, Niyazov A.
    Oncologist; 2023 Sep 07; 28(9):e737-e747. PubMed ID: 37014097
    [Abstract] [Full Text] [Related]

  • 11. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD, Coenen JL, van den Berg P, Westgeest HM, van den Eertwegh AJ, van Oort IM, Bos MM, Bergman AM, Hamberg P, Ten Tije AJ, Los M, Lolkema MP, de Wit R, Gelderblom H.
    Int J Cancer; 2015 Mar 15; 136(6):E760-72. PubMed ID: 25242736
    [Abstract] [Full Text] [Related]

  • 12. Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.
    de Bono JS, Smith MR, Saad F, Rathkopf DE, Mulders PFA, Small EJ, Shore ND, Fizazi K, De Porre P, Kheoh T, Li J, Todd MB, Ryan CJ, Flaig TW.
    Eur Urol; 2017 Apr 15; 71(4):656-664. PubMed ID: 27402060
    [Abstract] [Full Text] [Related]

  • 13. Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.
    Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.
    Eur Urol; 2015 Aug 15; 68(2):228-35. PubMed ID: 24837187
    [Abstract] [Full Text] [Related]

  • 14. Patient Preference Between Cabazitaxel and Docetaxel for First-line Chemotherapy in Metastatic Castration-resistant Prostate Cancer: The CABADOC Trial.
    Baciarello G, Delva R, Gravis G, Tazi Y, Beuzeboc P, Gross-Goupil M, Bompas E, Joly F, Greilsamer C, Hon TNT, Barthelemy P, Culine S, Berdah JF, Deblock M, Ratta R, Flechon A, Cheneau C, Maillard A, Martineau G, Borget I, Fizazi K, Groupe d’Etude des Tumeurs Uro-Genitales (GETUG)..
    Eur Urol; 2022 Mar 15; 81(3):234-240. PubMed ID: 34789394
    [Abstract] [Full Text] [Related]

  • 15. Outcomes of First-Line Abiraterone Acetate or Enzalutamide for Older Adults With Metastatic Castration-Resistant Prostate Cancer According to Use of Upfront Docetaxel for Metastatic Castration-Sensitive Prostate Cancer in an International Multicenter Registry: A SPARTACUSS-Meet-URO 26 Study.
    Fotia G, Saieva C, Lee-Ying R, Patrikidou A, Nuzzo PV, Zanardi E, Rossetti S, Davidsohn M, Eid M, El Zarif T, McClure H, Spinelli GP, Damassi A, Murianni V, Vauchier C, Oliveira TM, Malgeri A, Modesti M, Mestre RP, Valenca L, Ravi P, Santini D, Pignata S, De Giorgi U, Sweeney C, Heng D, Procopio G, Russo A, Francini E, Spartacuss Group.
    Clin Genitourin Cancer; 2024 Oct 15; 22(5):102185. PubMed ID: 39217072
    [Abstract] [Full Text] [Related]

  • 16. The influence of prior novel androgen receptor targeted therapy on the efficacy of cabazitaxel in men with metastatic castration-resistant prostate cancer.
    van Soest RJ, Nieuweboer AJ, de Morrée ES, Chitu D, Bergman AM, Goey SH, Bos MM, van der Meer N, Hamberg P, de Wit R, Mathijssen RH, Dutch Uro-Oncology Studygroup (DUOS).
    Eur J Cancer; 2015 Nov 15; 51(17):2562-9. PubMed ID: 26278646
    [Abstract] [Full Text] [Related]

  • 17. Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.
    Song W, Kwon GY, Kim JH, Lim JE, Jeon HG, Il Seo S, Jeon SS, Choi HY, Jeong BC, Lee HM.
    Oncotarget; 2016 Dec 13; 7(50):83735-83743. PubMed ID: 27863438
    [Abstract] [Full Text] [Related]

  • 18. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG, Agarwal N, Araujo JC, Sonpavde G.
    Eur Urol Focus; 2019 May 13; 5(3):369-380. PubMed ID: 29275145
    [Abstract] [Full Text] [Related]

  • 19. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL, Luber B, Schweizer MT, Nadal R, Antonarakis ES.
    Prostate; 2014 Sep 13; 74(13):1278-85. PubMed ID: 25053178
    [Abstract] [Full Text] [Related]

  • 20. A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer.
    Azad AA, Leibowitz-Amit R, Eigl BJ, Lester R, Wells JC, Murray RN, Kollmannsberger C, Heng DY, Joshua AM, Chi KN.
    Prostate; 2014 Nov 13; 74(15):1544-50. PubMed ID: 25175831
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.